Glycoconjugate vaccines to prevent group B streptococcal infections

被引：33

作者：

Paoletti, LC ^{[1
]}

Kasper, DL ^{[1
]}

机构：

[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab,Dept Med, Boston, MA 02115 USA

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2003年 / 3卷 / 06期

基金：

美国国家卫生研究院;

关键词：

clinical trials; group B Streptococcus; maternal vaccine; prevention of colonisation; vaccines;

D O I：

10.1517/14712598.3.6.975

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Group B Streptococcus (GBS) is an opportunistic pathogen of humans. At-risk populations include neonates born to colonised mothers, peripartum women, diabetics, and the elderly with underlying illnesses. Vaccines to prevent GBS disease have been developed by coupling purified capsular polysaccharide (CPS) antigen of GBS with an immunogenic protein carrier. Glycoconjugate vaccines against all nine currently identified GBS serotypes have been synthesised and shown to be immunogenic in mice, rabbits and baboons in preclinical trials. Healthy adults have safely received conjugate vaccines prepared with GBS types Ia, Ib, II, III, and V CPSs in Phase I and II clinical trials. These vaccines elicited CPS-specific antibody that opsonised GBS for in vitro killing by human peripheral blood leukocytes in the presence of complement. Results from these preclinical and clinical studies strongly suggest that GBS conjugate vaccines will be effective in preventing diseases caused by GBS.

引用

页码：975 / 984

页数：10

共 81 条

[51] Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII [J].

Paoletti, LC ;

Pinel, J ;

Johnson, KD ;

Reinap, B ;

Ross, RA ;

Kasper, DL .

JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (03) :892-895

[52] NEONATAL MOUSE PROTECTION AGAINST INFECTION WITH MULTIPLE GROUP-B STREPTOCOCCAL (GBS) SEROTYPES BY MATERNAL IMMUNIZATION WITH A TETRAVALENT GBS POLYSACCHARIDE-TETANUS TOROID CONJUGATE VACCINE [J].

PAOLETTI, LC ;

WESSELS, MR ;

RODEWALD, AK ;

SHROFF, AA ;

JENNINGS, HJ ;

KASPER, DL .

INFECTION AND IMMUNITY, 1994, 62 (08) :3236-3243

[53] Immunogenicity of group B Streptococcus type III polysaccharide tetanus toxoid vaccine in baboons [J].

Paoletti, LC ;

Kennedy, RC ;

Chanh, TC ;

Kasper, DL .

INFECTION AND IMMUNITY, 1996, 64 (02) :677-679

[54] Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate [J].

Paoletti, LC ;

Pinel, J ;

Kennedy, RC ;

Kasper, DL .

JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (02) :653-658

[55] Conjugate vaccines against group B Streptococcus types IV and VII [J].

Paoletti, LC ;

Kasper, DL .

JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (01) :123-126

[56]

PAOLETTI LC, 1990, J BIOL CHEM, V265, P18278

[57] Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines [J].

Paoletti, LC ;

Rench, MA ;

Kasper, DL ;

Molrine, D ;

Ambrosino, D ;

Baker, CJ .

INFECTION AND IMMUNITY, 2001, 69 (11) :6696-6701

[58]

Paoletti LC, 2000, GRAM-POSITIVE PATHOGENS, P137

[59] Potency of clinical group B streptococcal conjugate vaccines [J].

Paoletti, LC .

VACCINE, 2001, 19 (15-16) :2118-2126

[60] GROUP-B STREPTOCOCCUS TYPE-II POLYSACCHARIDE-TETANUS TOXOID CONJUGATE VACCINE [J].

PAOLETTI, LC ;

WESSELS, MR ;

MICHON, F ;

DIFABIO, J ;

JENNINGS, HJ ;

KASPER, DL .

INFECTION AND IMMUNITY, 1992, 60 (10) :4009-4014

← 1 2 3 4 5 6 7 8 9 →